Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: Long-term results by the NHLCSG

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1941-1948

  Olivieri, A ^a   Santini, G ^b   Patti, C ^c   Chisesi, T ^d   De Souza, C ^e   Rubagotti, A ^b   Aversa, S ^f   Billio, A ^g   Porcellini, A ^f   Candela, M ^a   Centurioni, R ^h   Congiu, A M ^b   Brunori, M ^a   Nati, S ^b   Spriano, M ^b   Vimercati, R ^b   Marino, G ^b   Contu, A ⁱ   Tedeschi, L ^j   Majolino, I ^k   Crugnola, M ^l   Sertoli, M R ^b   more..

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY OF CAMPINAS   (Brazil)

^f General Hospital   (Italy)

^g San Maurizio Hospital   (Italy)

^h General Hospital   (Italy)

ⁱ Sassari General Hospital   (Italy)

^j SAN CARLO BORROMEO HOSPITAL   (Italy)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^l UNIVERSITY OF PARMA   (Italy)

more..

Author keywords

Autologous stem cell transplantation; High dose sequential therapy; High grade NHL; VACOP B

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; VINCRISTINE;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEPATITIS; ADOLESCENT; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW TUMOR; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; ENCEPHALITIS; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HEART FAILURE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LIVER TOXICITY; LONG TERM CARE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 28444484995     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi399     Document Type: Article

References (30)

1. Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination regimen (m-BACOD) with standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-1349.
2. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.N Engl J Med 1993; 328: 1002-1006.
3. Sertoli MR, Santini G, Chisesi T et al. MACOP-B versus proMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphomas: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1994; 12: 1366-1374.
4. Cabanillas F, Hagemeister FB, Mc Laughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-410.
5. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-122.
6. Velasquez WS, Mc Laughlin P, Tucker S et al. ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
7. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-1497.
8. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report for the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.
9. Verdonck LF, Van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-1051.
10. Martelli M, Vignetti M, Zinzani PL et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabin in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian Multicenter Study. J Clin Oncol 1996; 14: 534-542.
11. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994; 12: 2543-2551.
12. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 1997; 15: 1131-1137.
13. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adult Study. J Clin Oncol 2000; 18: 3025-3030.
14. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
15. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22-30.
16. Kaiser U, Uebelacker I, Abel U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 2002; 20: 4413-4419.
17. Martelli M, Gherlinzoni F, De Renzo A et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255-1262.
18. Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479.
19. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
20. Santini G, Salvano L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796-2802.
21. The non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
22. Carbone PP, Kaplan HS, Musshoff K et al. report of the Committee of Hodgkin's Disease Staging classification. Cancer Res 1971; 31: 1860-1861.
23. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
24. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244-1253.
25. O'Reilly SE, Hoskins P, Klimo P, Connors JM: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2 (Suppl 1): 17-23.
26. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
28. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
29. Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus ritux-imab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
30. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.